# US 2021/0330642 A1 · Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330642 A1
- Document ID: US20210330642A1
- Status: Published application
- Kind: A1
- Application number: 16/618,792
- Filed: 2019-07-30
- Published: 2021-10-28
- Earliest claimed: 2018-07-31
- Assignees: Ascentage Pharma (Suzhou) Co., Ltd.
- Applicants: Ascentage Pharma (Suzhou) Co., Ltd.
- Inventors: Dajun YANG; Yifan ZHAI; Douglas Dong FANG; Guangfeng WANG; Qiuqiong TANG; Wentao PAN; Jiao JI
- Web page: https://patentgrep.com/patent/US20210330642A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor.

## Claims

### Claim 1

A method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and/or a therapeutically effective amount of a tubulin inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the IAP inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
X is selected from
and —SO2—;
Y is selected from —NH—, —O—, —S—, and absence;
R is selected from
—C3-6 cycloalkylene
R1 is selected from
—(CH2)4-10—,
Z is O, S or NH;
n is 0, 1 or 2;
Ring A is a C4-8 aliphatic ring; and
B ring is phenyl, naphthyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, and B ring is optionally substituted.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, the compound of formula (I) is:

### Claim at position 5

7-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the modulator of an immune checkpoint molecule is anti-PD-1 antibody, anti-CLTA antibody or anti PD-L1 antibody.

### Claim 12 (depends on 1)

The method of claim 1, wherein the modulator of an immune checkpoint molecule is pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, durvalumab, AGEN-1884, BMS-986016, CS1001, CS-1002, LAG525, MBG453, MEDI-570, OREG-103/BY40, lirilumab, tremelimumab, JS001, SHR-1210, BGB-A317, IBI-308, REGN2810, JS003, SHR-1316, KN035 or BMS-936559.

### Claim 13 (depends on 1)

The method of claim 1, wherein the tubulin inhibitor is selected from paclitaxel (Taxol), epothilone, docetaxel, discodermolide, colchicine, combretastatin, 2-methoxyestradiol, methoxybenzenesulfonamide (E7010), vinblastine, vincristine, vinorelbine, vinfluine, dolastatin, halichondrin, hemiasterlin and cryptophysin 52.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the IAP inhibitor is APG-1387; the modulator of an immune checkpoint molecule is anti-PD-1 antibody, the tubulin inhibitor is docetaxel or paclitaxel.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is selected from adrenocortical cancer, anal cancer, cholangiocarcinoma, bladder cancer, bone cancer, bone metastasis cancer, adult brain/central nervous system tumor, childhood brain/central nervous system tumor, breast cancer, male breast cancer, childhood cancer, primary cancer unknown cancer, Castleman disease, Merkel cell carcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma family tumor, eye cancer, gallbladder cancer, digestive tract cancer, gastrointestinal stromal tumor (GIST), trophoblastic cancer, head and neck cancer, Kaposi's sarcoma, renal cancer, renal cell cancer, laryngeal and hypopharyngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, cutaneous lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal and nasalsinus cancer, nasopharyngeal cancer, neuroblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, childhood non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, malignant pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, small intestinal cancer, testicular cancer, thymic cancer, thyroid cancer, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, urothelial cancer, microsatellite instability solid tumor and choriocarcinoma, and preferably, the cancer is head and neck cancer, microsatellite instability solid tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, renal cell cancer, bladder cancer, melanoma, squamous cell carcinoma, Merkel cell tumor, urothelial cancer and colorectal cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein the IAP inhibitor is administered in an amount of about 0.005 mg/day to about 5000 mg/day.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the modulator of an immune checkpoint molecule or the tubulin inhibitor is administered in an amount of about 0.005 mg/week to about 5000 mg/week.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the IAP inhibitor, modulator of an immune checkpoint molecule, and tubulin inhibitor are administered together, concurrently, sequentially or alternately.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the IAP inhibitor, modulator of an immune checkpoint molecule or tubulin inhibitor is administered for one or more courses of treatment, wherein each course of treatment lasts for at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, at least 22 days, at least 23 days, at least 24 days, at least 25 days, at least 30 days, at least 35 days, at least 40 days, at least 45 days or at least 50 days; wherein for each course of treatment, administration is performed 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times; and the interval between every two courses of treatment is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days, two weeks, three weeks, four weeks, one month or two months.

### Claim at position 19

24-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the individual suffers from a refractory cancer, a recurrent cancer or a resistant cancer that is resistant to a cancer therapy comprising the modulator of an immune checkpoint molecule and/or the tubulin inhibitor.

### Claim 28 (depends on 2)

A pharmaceutical composition comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, a tubulin inhibitor, and a pharmaceutically acceptable carrier;
wherein
the IAP inhibitor is defined as in claim 2.

### Claim 29 (depends on 2)

A kit comprising:
(a) a first component in a first container, the first component comprising an IAP inhibitor as defined in claim 2;
(b) a second component in a second container, the second component comprising a modulator of an immune checkpoint molecule;
(c) a third component in a third container, the third component comprising a tubulin inhibitor.

### Claim 30 (depends on 2)

A method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor as defined in claim 2 and a therapeutically effective amount of a modulator of an immune checkpoint molecule.

### Claim 31 (depends on 30)

The method of claim 30, wherein the cancer is advanced solid tumor or hematologic malignancies, and preferably, the cancer is metastatic pancreatic cancer, colorectal cancer, ovarian cancer, lymphoma, or liver cancer (such as hepatocellular carcinoma).

### Claim 32 (depends on 2)

A pharmaceutical composition comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and a pharmaceutically acceptable carrier;
wherein
the IAP inhibitor is as defined in claim 2.

### Claim 33 (depends on 2)

A kit comprising:
(a) a first component in a first container, the first component comprising an IAP inhibitor as defined in claim 2;
(b) a second component in a second container, the second component comprising a modulator of an immune checkpoint molecule.

### Claim 34 (depends on 1)

The method of claim 1, wherein the method comprises at least one 21-day treatment cycle, wherein the IAP inhibitor is administrated on days 1, 8 and 15 of the consecutive 3-weeks of the treatment cycle.

### Claim 35 (depends on 34)

The method of claim 34, wherein the IAP inhibitor is APG-1387.

### Claim 36 (depends on 35)

The method of claim 35, wherein APG-1387 is administered via an intravenous infusion.

### Claim 37 (depends on 34)

The method of claim 34, wherein the therapeutically effective amount is from about 15 mg to about 100 mg, or is from 20 to 45 mg, or from 20 mg to 60 mg of IAP inhibitor.

### Claim 38 (depends on 34)

The method of claim 34, wherein the therapeutically effective amount is 20 mg, 30 mg, 45 mg, 60 mg or 80 mg.

### Claim at position 32

39-42. (canceled)

### Claim 43 (depends on 34)

The method of claim 34, wherein the cancer is advanced solid tumor or hematologic malignancies, and preferably, the cancer is metastatic pancreatic cancer, colorectal cancer, ovarian cancer, lymphoma, or liver cancer (such as hepatocellular carcinoma).

### Claim 44 (depends on 34)

The method of claim 34, wherein the method further comprises administering a therapeutically effective amount of carboplatin.

### Claim at position 35

45-46. (canceled)

### Claim 47 (depends on 34)

The method of claim 34, wherein the IAP inhibitor is APG-1387 and the modulator of an immune checkpoint molecule is pembrolizumab, and wherein APG-1387 is administered with pembrolizumab for treating a patient suffering from advanced solid tumors or hematologic malignancies.

### Claim 48 (depends on 34)

The method of claim 34, wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is pembrolizumab, and the tubulin inhibitor is docetaxel, and wherein APG-1387 is administered with pembrolizumab and docetaxel for treating a patient suffering from advanced solid tumors or hematologic malignancies.

### Claim 49

(canceled)

### Claim 50 (depends on 44)

The method of claim 44, wherein the IAP inhibitor is APG-1387 and the tubulin inhibitor is paclitaxel, and wherein APG-1387 is administered with paclitaxel and carboplatin for treating a patient suffering from advanced solid tumors.

### Claim at position 40

51-59. (canceled)
